Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

Clinical Evidence in Locoregional and Late Recurrence Settings

Clinical Highlights | TransNEOS Study | WSG ADAPT Trial

Locoregional recurrence risk

A significant association was observed in studies between the Recurrence Score® result and the risk for locoregional recurrence (LRR), in both node-negative and node-positive patients.1,2 The results of these studies have potential clinical implications for locoregional therapy decisions for patients with node-negative or node-positive ER-positive breast cancer.1-3

Icon minus circle

The Recurrence Score result in node-negative patients was an independent, significant predictor of LRR along with age and type of initial treatment.

Icon plus

In the node-positive setting, the Recurrence Score result is an independent predictor of LRR along with number of positive nodes and tumor size. These findings may have clinical implications regarding patient selection for postmastectomy chest wall and regional nodal radiation therapy (XRT) and postlumpectomy regional nodal XRT in node-positive, ER-positive patients treated with adjuvant chemoendocrine therapy.

In postmenopausal women with a node-positive, estrogen receptor– or progesterone receptor–positive breast cancer, intermediate or high recurrence score was associated with a significantly increased risk of locoregional recurrence3

Late recurrence risk

The challenge facing physicians is identifying which patients are at higher risk of distant recurrence after 5 years of hormone therapy.

The Oncotype DX Breast Recurrence Score® test may identify patients who are at higher risk of distant recurrence beyond 5 years and might have greater benefit from extended hormonal therapy.4

  • The association between quantitative ER and tamoxifen benefit has been shown in the landmark NSABP B-14 study5
  • The Recurrence Score result was significantly associated with prediction of late distant recurrence (years 5-15) in patients with higher quantitative ER expression (>9.1)5



Explore clinical evidence

American Society of Clinical Oncology (ASCO) and ASCO are registered trademarks of ASCO; ASCO do not endorse any product or therapy.

Icon doctor

Use our online physician portal

Order tests, access results, receive updates, and more in one place.
Sign up now